Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells.
Pruitt K, Ulkü AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM. Pruitt K, et al. Among authors: muniz medina vm. J Biol Chem. 2005 Jun 17;280(24):23363-70. doi: 10.1074/jbc.M503083200. Epub 2005 Apr 14. J Biol Chem. 2005. PMID: 15831492 Free article.
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells.
Chen R, Rajan S, Overstreet MG, Hurt EM, Thomas SB, Muniz-Medina V, Ward C, Sadowska A, Fleming R, Karanth S, Breen S, Zheng B, Wu Y, Iverson WO, Novick S, O'Day T, Shah DP, Dimasi N, Tiberghien AC, Osbourn J, Walker J. Chen R, et al. Mol Cancer Ther. 2020 Aug;19(8):1649-1659. doi: 10.1158/1535-7163.MCT-19-0482. Epub 2020 May 13. Mol Cancer Ther. 2020. PMID: 32404408
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR. Li JY, et al. Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008. Cancer Cell. 2016. PMID: 26766593 Free article.
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
White JB, Fleming R, Masterson L, Ruddle BT, Zhong H, Fazenbaker C, Strout P, Rosenthal K, Reed M, Muniz-Medina V, Howard P, Dixit R, Wu H, Hinrichs MJ, Gao C, Dimasi N. White JB, et al. MAbs. 2019 Apr;11(3):500-515. doi: 10.1080/19420862.2019.1578611. Epub 2019 Mar 5. MAbs. 2019. PMID: 30835621 Free PMC article.
Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.
Sun J, Hao W, Fillmore N, Ma H, Springer D, Yu ZX, Sadowska A, Garcia A, Chen R, Muniz-Medina V, Rosenthal K, Lin J, Kuruvilla D, Osbourn J, Karathanasis SK, Walker J, Murphy E. Sun J, et al. J Am Heart Assoc. 2019 Dec 17;8(24):e013465. doi: 10.1161/JAHA.119.013465. Epub 2019 Dec 10. J Am Heart Assoc. 2019. PMID: 31818212 Free PMC article.
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Masson Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR. Li JY, et al. Cancer Cell. 2019 Jun 10;35(6):948-949. doi: 10.1016/j.ccell.2019.05.010. Cancer Cell. 2019. PMID: 31185215 Free article. No abstract available.
14 results